RxDoctor Payments Data

Amy Johnson, MD

Family Medicine · Pocomoke, MDNPI 1245292853

Payments from drug & device makers

$902in general payments, 2019–2025

Across 39 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • GSK$202
  • AstraZeneca$117
  • Lilly USA, LLC$82
  • Exact Sciences$68
  • Pfizer$63
  • plus $168 from 7 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$202
GSK3$202
AstraZeneca7$117
Lilly USA, LLC4$82
Exact Sciences3$68
Pfizer3$63
Amgen2$49
Novo Nordisk2$30
Dexcom, Inc.1$22
GE HealthCare1$20
Merck1$18
Boston Scientific1$17
Bayer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$902 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$102,794
Medicare patients
220
Services billed
1,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$82,232
OzempicSemaglutide44$77,590
EliquisApixaban48$44,948
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp20$4,991
SymbicortBudesonide/Formoterol Fumarate19$4,443
Olmesartan Medoxomil94$4,230
Breo ElliptaFluticasone/Vilanterol11$4,174
Estradiol42$3,853
Rosuvastatin Calcium123$3,522
Esomeprazole Magnesium43$3,471
Atorvastatin Calcium211$3,318
Metoprolol Succinate192$3,153
Albuterol Sulfate HfaAlbuterol Sulfate75$1,845
SynthroidLevothyroxine Sodium14$1,827
Gabapentin112$1,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$82$82,23269 claims
Novo NordiskOzempic$30$77,59044 claims
PfizerEliquis$63$44,94848 claims
AstraZenecaSymbicort$117$4,44319 claims
GSKBreo Ellipta$202$4,17411 claims
AbbVieSynthroid$202$1,82714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Pocomoke

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →